
In a JAMA Network Open study published Sept. 11, researchers wanted to take a deeper look into PrEP regimens’ impact on cardiometabolic health, as it is understudied. To do so they examined the risk of incident hypertension and statin use among adult health plan members starting PrEP with tenofovir alafenamide fumarate (TAF) compared adults taking tenofovir disoproxil fumarate (TDF).



























